These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 18757092)

  • 1. BEAUTIFUL results--the slower, the better?
    Reil JC; Böhm M
    Lancet; 2008 Sep; 372(9641):779-80. PubMed ID: 18757092
    [No Abstract]   [Full Text] [Related]  

  • 2. Letters to the editor: comments on the BEAUTIfUL study.
    Bonny A; Yitemben IM; Hamdaoui B; Larrazet F
    Cardiovasc J Afr; 2008; 19(6):323-24, discussion 324. PubMed ID: 19104735
    [No Abstract]   [Full Text] [Related]  

  • 3. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial.
    Fox K; Ford I; Steg PG; Tendera M; Robertson M; Ferrari R;
    Lancet; 2008 Sep; 372(9641):817-21. PubMed ID: 18757091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials.
    Fox K; Komajda M; Ford I; Robertson M; Böhm M; Borer JS; Steg PG; Tavazzi L; Tendera M; Ferrari R; Swedberg K
    Eur Heart J; 2013 Aug; 34(29):2263-70. PubMed ID: 23536611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interpreting clinical trials: the 'beautiful' case.
    Agewall S; Atar D
    Fundam Clin Pharmacol; 2009 Apr; 23(2):261-2. PubMed ID: 19236485
    [No Abstract]   [Full Text] [Related]  

  • 6. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.
    Fox K; Ford I; Steg PG; Tendera M; Ferrari R;
    Lancet; 2008 Sep; 372(9641):807-16. PubMed ID: 18757088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Coronary heart disease. Rapid heart rate has an unfavorable prognosis].
    Einecke D
    MMW Fortschr Med; 2008 Sep; 150(38):12-4. PubMed ID: 18983046
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of ivabradine plus beta-blockers versus beta -blocker therapy only.
    Aalbers J
    Cardiovasc J Afr; 2010; 21(2):116. PubMed ID: 20532439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Heart rate: a risk factor or an epiphenomenon?].
    Metra M; Zacà V; Lombardi C; Bugatti S; Dei Cas L
    G Ital Cardiol (Rome); 2010 Mar; 11(3):209-20. PubMed ID: 20550061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The BEAUTIFUL study].
    Gensini GF; Lanza GA
    G Ital Cardiol (Rome); 2009 Apr; 10(4):203-8. PubMed ID: 19475873
    [No Abstract]   [Full Text] [Related]  

  • 11. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
    Fox K; Ferrari R; Tendera M; Steg PG; Ford I;
    Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy).
    Tendera M; Talajic M; Robertson M; Tardif JC; Ferrari R; Ford I; Steg PG; Fox K;
    Am J Cardiol; 2011 Mar; 107(6):805-11. PubMed ID: 21247517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Symptomatic coronary heart diseases. Combination therapy is successful in general practice].
    MMW Fortschr Med; 2014 Nov; 156(20):75. PubMed ID: 25543378
    [No Abstract]   [Full Text] [Related]  

  • 14. Carvedilol for heart failure: more than just a beta-blocker?
    Cleland JG
    Br J Hosp Med; 1997 Nov 19-Dec 9; 58(10):493-7. PubMed ID: 10193451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of heart rate in cardiovascular diseases: how the results of the BEAUTIFUL study change clinical practice.
    Bruguera Cortada J; Varela A
    Am J Cardiovasc Drugs; 2009; 9 Suppl 1():9-12. PubMed ID: 20000882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Resting heart rate as prognostic parameter--a slow rate indicates strength].
    Füessl HS
    MMW Fortschr Med; 2008 May; 150(21):12-4, 16. PubMed ID: 18575247
    [No Abstract]   [Full Text] [Related]  

  • 17. Ivabradine: beyond heart rate control.
    Riccioni G; Vitulano N; D'Orazio N
    Adv Ther; 2009 Jan; 26(1):12-24. PubMed ID: 19165437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Attaining therapy relevant goals with ivabradin].
    Lohmann M
    MMW Fortschr Med; 2014 Oct; 156(17):71. PubMed ID: 25417482
    [No Abstract]   [Full Text] [Related]  

  • 19. Going for gold, from Beijing to Munich, highlights from the ESC 2008 Congress: BEAUTIFUL, GISSI-HF, and potential new therapies for acute decompensated heart failure.
    Kalra P; Pauriah M; Elder D; Lang CC
    Cardiovasc Ther; 2008; 26(4):235-7. PubMed ID: 19035873
    [No Abstract]   [Full Text] [Related]  

  • 20. β-Blockers and ivabradine differentially affect cardiopulmonary function and left ventricular filling index.
    Fischer-Rasokat U; Honold J; Lochmann D; Wolter S; Liebetrau C; Fichtlscherer S; Möllmann H; Spyridopoulos I; Hamm CW
    Clin Res Cardiol; 2016 Jun; 105(6):527-34. PubMed ID: 26687495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.